A Study of NDI 1150-101 in Patients With Solid Tumors (NCT05128487)
A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of NDI-101150 Administered as Monotherapy or in Combination With Pembrolizumab in Patients With Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) and to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of NDI-101150 given as monotherapy or in combination with pembrolizumab in adult patients with advanced solid tumors.
Who can join: Review the eligibility criteria below.
Location: Honor Health Research Institute — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (19 Sites)
- Honor Health Research Institute — Scottsdale, Arizona
- Yale Cancer Center — New Haven, Connecticut
- Georgetown University — Washington D.C., District of Columbia
- Ocala Oncology Center — Ocala, Florida
- Norton Cancer Institute — Louisville, Kentucky
- University of Maryland Greenebaum Comprehensive Cancer Center — Baltimore, Maryland
- Henry Ford Cancer — Detroit, Michigan
- HealthPartners Cancer Research Center — Saint Paul, Minnesota
- Washington University — St Louis, Missouri
- Hackensack University — Hackensack, New Jersey
- Columbia University Irving Medical Center — New York, New York
- Stephenson Cancer Center — Oklahoma City, Oklahoma
- Texas Oncology - Baylor Charles A. Sammons Cancer Center — Dallas, Texas
- Center for Oncology and Blood Disorders — Houston, Texas
- Oncology Consultants — Houston, Texas
- NEXT Oncology — San Antonio, Texas
- NEXT Oncology — Fairfax, Virginia
- Northwest Medical Specialties — Tacoma, Washington
- University of Wisconsin — Madison, Wisconsin
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor
- A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors — Houston, Texas
- A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer — Middletown, New Jersey
- A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer — Basking Ridge, New Jersey
- Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors — Chicago, Illinois
- A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors — New York, New York
- Concurrent Azeliragon With Craniospinal Irradiation — New York, New York
Explore by condition: All Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.